There are sparse published data relating to the pharmacokinetic properties of artemether, 25 lumefantrine and their active metabolites in children, especially desbutyl-lumefantrine. We 26 studied 13 Papua New Guinean children aged 5-10 years with uncomplicated malaria who 27 received the six recommended doses of artemether (1.7 mg/kg) plus lumefantrine (10 mg/kg) 28
Introduction 50 51
Artemether-lumefantrine (AL) is a fixed-dose combination therapy used widely for the 52 treatment of malaria (35) . Artemether (ARM) is a lipophilic artemisinin derivative that is 53 converted in vivo to dihydroartemisinin (DHA), an active metabolite. Both ARM and DHA 54 have short half-lives (14, 20-22, 25-26, 32 ) but a rapid effect on parasitemia. Lumefantrine 55 (LUM) is a highly lipophilic drug with a longer half-life (11, 13-14, 20-21, 25, 31) which is 56 combined with ARM primarily to prevent late recrudescence. Although the pharmacokinetic 57
properties of ARM, DHA and LUM have been well documented in adults (4-5, 11, 13-15, 20-58 23, 25, 31) , there are scant and inconsistent data relating to the disposition of desbutyl-59 lumefantrine (DBL), a potent LUM metabolite (27, (29) (30) 33 ) that may influence AL 60 treatment outcome (33). Reported plasma DBL:LUM concentration ratios after AL dosing in 61 adults differ >10-fold (15, 25) , while the pharmacokinetic properties of DBL in children are 62 unknown. In addition, although several studies have attempted to characterize LUM 63 disposition in children with malaria (1, 16, 26) , methodologic issues complicate their 64 comparison with adult data. One study involving a limited sampling schedule suggested that 65 AL-treated children with malaria receive an inadequate dose of LUM relative to healthy 66 adults (26), while the other studies either used pooled plasma concentrations (1) or used a 67 truncated sampling schedule inadequate to characterize LUM pharmacokinetics (16) . 68
69
In view of this situation, we have characterized the population pharmacokinetics of ARM, 70 LUM and their metabolites in pediatric malaria using a rich sampling schedule to assess 71 potential differences in disposition between children and adults, and to add to the limited data 72 on DBL disposition and its role in AL treatment outcome. washed twice with 1M acetic acid (1 milliliter), followed by 20% v/v methanol in 1M acetic 126 acid (1 milliliter). The column was dried under low vacuum for 30 min and the retained drugs 127 eluted using 2 milliliter t-butyl chloride: ethyl acetate (80:20% v/v). The eluate was then 128 evaporated under vacuum at 35°C and reconstituted in 50 microliter mobile phase and kept 129 overnight to equilibrate the α and β anomers of DHA (7). Only the α-anomer was used for 130 quantification. The injection volume was 10 microliter. 131
132
The liquid chromatography-mass spectrometry (LC-MS) system used was a single quad mass 133 spectrometer (Shimadzu, Kyoto, Japan) with electrospray ionization (ESI) and atmospheric 134 pressure ionization (APCI) systems. Assays were performed with 20 mM ammonium formate 135 (pH 5):acetonitrile in 0.1% formic acid (40:60) at a flow rate of 0.2 milliliter/min, and 136 chromatographic separation undertaken at ambient temperature on a Synergy fusion-RP C 18 137 (150 mm x 2.0 mm i.d.) column coupled with a 4 mm x 3 mm i.d., 5 µm particle C 18 guard 138 column (Phenomenex, Lane Cove, Australia). Retention times were 4.5, 7.5 and 12.7 min for 139 DHA, artemisinin and ARM, respectively. Optimized mass spectra were acquired with an 140 interface voltage of 4.5 kV, a detector voltage of 1 kV, a heat block temperature of 400°C and 141 a desolvation gas temperature of 250°C. Nitrogen was used as a nebulizer gas at a flow rate 142 of 1.5 liter/min and dry gas flow of 10 liter/min. Quantitation was performed by selected ion 143 monitoring using the dual ionization source mode. The predominant fragmented ions m/z 221 144 for ARM and m/z 221 for DHA were used. For artemisinin, m/z=283 was monitored. 145
146
Standard curves were linear (r 2 ≥0.999). Chromatographic data (peak area ratio of 147 DHA:artemisinin and ARM:artemisinin) were processed using LAB Solution software 148 (Version 5, Shimadzu, Japan). No matrix effect (ion suppression/enhancement) was observed 149 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from 7 under methodologies described elsewhere (24), and performance of both assays, assessed as 150 intra-and inter-day relative standard deviations across relevant concentration ranges, was 151 similar to that published previously (7, 18) . Inter-day accuracies of QC assays were <15% of 152 nominal values on all occasions. The limits of quantification and detection for DHA and 153 ARM were 2 and 1 μg/liter, and 5 and 2 μg/liter, respectively. 154 155 LUM and DBL were quantified in plasma using a validated ultra-high-performance liquid 156 chromatography-tandem mass spectrometry assay as previously described (33). The linear 157 range for LUM was 20-20,000 ng/milliliter, and inter-day variability was 4.94%, 4.93%, 158 7.16% and 11.23% and intra-day variability 2.83%, 4.41%, 4.11%, 9.55% at 20,000, 2,000, 159 200 and 20 ng/milliliter, respectively. For DBL, the linear range was 0.5 -100 ng/milliliter, 160 and inter-day variability was 3.36%, 3.47%, 9.98% and 6.74% and intra-day variability 161 2.47%, 3.46%, 8.16% and 3.48% at 50, 10, 1 and 0.5 ng/milliliter, respectively. As a LC-162 MS/MS method was used for DBL, matrix effects were assessed where between subject 163 variability was 3.37%, 4.47% and 9.43% at 50, 10 and 1 ng/milliliter, respectively. 164
165

Pharmacokinetic modeling 166
Log e (natural log) plasma concentration-time datasets for LUM with DBL and ARM with 167 DHA were analyzed by nonlinear mixed effect modeling using NONMEM (v 6.2 x F met-DBL ) will be used for simplicity. 194
195
As 45% and 12% of plasma ARM and DHA concentrations, respectively, were below the 196 limit of quantification (BLQ), we used a published method known to produce reliable 197 pharmacokinetic parameters in this situation (9-10). The method (known as M3 (2) The applicability of the final population models to younger patients from the present sample 233 was assessed using a numerical predictive check. Day 7 plasma LUM concentrations from a 234 previous study (18) from children aged 0.5 to 5 years were compared with simulated data 235 from the final models. The actual and simulated number of data points above and below the 236 20%, 40%, 60%, 80%, 90% and 95% simulated prediction intervals (PI) were compared. 237
238
Statistical analysis 239
Changes in hemoglobin, glucose and audiometric data over time were assessed using the 240
Wilcoxon signed-rank test. The AUC 0-∞ s of DBL and LUM were compared between subjects 241 with or without recurrent parasitemia using the Mann-Whitney U test. A two-tailed level of 242 significance of 0.05 was considered significant for all comparisons. 
Clinical characteristics and course 248
The baseline characteristics of the 13 recruited children are summarized in Table 1 . Eleven 249 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from 11 had a mono-infection (9 P. falciparium, 2 P. malariae) on confirmatory expert microscopy, 250 while 2 had a mixed P. falciparum/vivax infection. AL treatment was well tolerated and 251 reported symptoms were mild/moderate, short-lived (<3 days) and consistent with clinical 252 features of uncomplicated malaria. Initial fever and parasite clearance were <48 h in all cases. 253
254
By 28 days of follow-up, three children had developed slide-positive P. vivax (two had P. 255 vivax at enrolment) and two children had developed P. falciparum (one had P. falciparum at 256 enrolment). By 42 days of follow-up, five children had been diagnosed with P. vivax (two 257 had P. vivax at enrolment) and three with P. falciparum (two had P. falciparum at 258 enrolment). These data are consistent with the PCR uncorrected results of a previous larger 259 comparative treatment trial in younger children performed at the same location (18). The 260 recurrent P. vivax parasitaemia could have resulted from i) recrudescent infection in those 261 infected with this parasite before treatment, ii) acquisition of a new P. vivax infection after 262 treatment or, since no primaquine therapy was administered, iii) appearance of P. vivax from 263 hypnozoites present in the liver at study entry. For P. falciparum parasitemia detected during 264 follow-up, this could have represented recrudescence or re-infection. 265
266
The mean hemoglobin concentration was significantly higher on day 28 compared to 267 enrolment (10.7 vs 8.9 g/liter, P<0.01). There was no significant change in blood glucose 268 over the first three days of enrolment or audiometric findings over 28 days (data not shown). 
288
The final model parameter estimates and the bootstrap results are summarized in Table 2 . DBL levels in the younger children were higher than expected from the model. 301
302
Initial modeling of ARM/DHA datasets proved difficult given the large proportion of BLQ 303 data (45% and 12% for ARM and DHA respectively). Once these data were incorporated into 304 the model using the method 'M3' in Ahn et al. (2), more acceptable models were obtained. 305
The dispositions of ARM and DHA were best described by a 2-compartment model for ARM 306 and a 1-compartment model for DHA. The structural model parameters were k a , V C /F ARM , 307 In the present study of PNG children with uncomplicated malaria treated with a conventional 338 AL regimen, rich datasets of plasma concentrations of LUM, ARM and their active 339 metabolites measured during an extended follow-up period were successfully analyzed using 340 population pharmacokinetic modeling that allowed for a high proportion of BLQ plasma 341 ARM and DHA concentrations. Our analyses included the first compartmental PK analysis of 342 plasma DBL levels. We found that current dose recommendations for AL in children result in 343 a LUM AUC similar to that achieved in adults, despite children receiving a higher average 344 mg/kg dose relative to a 50 kg adult. However, the subgroup of children weighing 12.5-15 kg 345 receive the lowest mg/kg dose and may be at risk of under-dosing. Three studies, all from Africa, have examined LUM pharmacokinetics after AL treatment in 348 children. The first and simplest compared crushed tablets and a dispersible formulation using 349 a pooled analysis of single blood sample taken at one of six time-points during a 14-day 350 period from 726 children aged <12 years (1). The LUM AUC for both formulations was 351 higher than in the present study (574,000 and 636,000 vs 459,980 µg h liter -1 ). In the second 352 study (26), six blood samples were taken from children aged 5-13 years starting when the last 353 AL dose was given and the LUM AUC 60-∞ was calculated using non-compartmental analysis. 354
When we used our final models to generate an AUC 60-∞ , this was higher (257,010 vs 210,000 355 µg h liter -1 ). Based on their data, the authors reported that children have lower levels of 356 exposure to LUM than adults using recommended AL dose schedules (26). A third study of 357 children aged 1-10 years utilized a population approach (16) but there was no sampling 358 beyond 72 h and no secondary pharmacokinetic parameters were provided. A comparison 359 with LUM disposition in the present study was, therefore, not possible. 360
361
Comparisons of LUM AUC between studies in adults is also difficult as some report AUC 362 from the first dose while others use AUC 60-∞ . Table 5 summarizes the available data for both 363 measures of drug exposure. There is a difference between LUM exposure in healthy adults 364 and subjects with malaria, but the AUCs for non-pregnant adults, pregnant adults and 365 children with malaria are similar. Current AL dose recommendations for children ensure that 366 those weighing 15-35 kg receive a 35% higher average mg/kg dose than a 50 kg adult, but 367 those weighing 12.5-15 kg receive a lower mg/kg dose. The AUC data support the higher 368 average mg/kg dose in children and suggest that those weighing 12.5 -15 kg should receive 2 369 tablets rather than 1 to avoid under-dosing while not exceeding the highest recommended 370 mg/kg dose ( Figure 6 ). As LUM exposure, measured either as AUC or day 7 levels, has 371 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from 16 previously been shown to be a prime determinate of efficacy (12, 28) , it is important that 372 under-dosing is avoided. 373
374
The three studies of AL in children also measured plasma ARM/DHA concentrations (1, 16, 375 26). The first was not able to calculate AUCs from pooled concentration data due to a sparse 376 sampling schedule (1). The second employed a limited sampling schedule starting from the 377 last AL dose (26), and the AUCs were therefore lower than those of the present study (168 vs 378 217 µg h liter -1 for ARM and 382 vs 402 µg h liter -1 for DHA). The population approach 379 used in the third study (16) produced a similar model of the disposition of ARM (two 380 compartments) and DHA (one compartment) to that of the present study. The authors 381 reported a similar increase in CL/F ARM with each dose (57% vs 67.8 % in our children) and a 382 higher RV (61% vs 51.6% and 82 % vs 53.3% for ARM and DHA respectively), the latter 383 observation likely a reflection of the fact that many plasma concentrations were close to or 384 below the LOQ. As no secondary PK parameters were provided, a comparison of AUCs 385
could not be performed. However the half-lives of ARM, estimated from the pharmacokinetic 386 parameters provided, were longer than those in our children (0.89 vs 0.62 h and 32.0 vs 16.4 387 h for distribution and elimination, respectively, of the first dose), while the elimination half-388 life of DHA was shorter (0.38 vs 0.80 h). 389
390
The AUCs for ARM and DHA in the present study were similar to those reported previously 391 in adults with malaria (22, 25) but higher than those in healthy adults (14, (20) (21) . Our 392 terminal elimination half-life for ARM was longer than those reported in these studies (16.4 393 vs 1.5-3.9 h) while for DHA it was shorter (0.80 vs 1.2-2.1 h). The adult studies used non-394 compartmental methods to determine these half-lives and this may account for the 395 was from a study of pregnant Thai women with malaria in which sampling started after the 403 last dose and AUC 60-∞ was reported. The difference between these values can, at least in part, 404 be explained by the study designs as the metabolite-to-parent percentage calculated from 405 AUC 60-∞ in the present study is more than double for AUC 0-168 (1.96 vs 0.76 %). However it 406 is likely that ethnicity and pregnancy contribute to the difference. Age may also influence 407 metabolic conversion of LUM to DBL as our PK model was able to predict concentrations of 408 LUM but not DBL in younger children effectively. It is uncertain as to whether malaria itself 409 also influences the ratio since it was 0.45%, within the range of studies of malaria, after a 410 single dose of AL in 22 healthy adults (19). 411
412
As reported previously (25) DBL had a longer terminal elimination half-life than LUM in the 413 present study (141 vs 123 h) and therefore the DBL:LUM ratio will increase with time. 414
Although the ratios found in available studies are low, the in vitro potency of DBL is between 415 2.2 and 7.2 times that of LUM (27, (29) (30) 33) and it may therefore contribute to therapeutic 416 outcome. We found a combined weighted LUM/DBL AUC was more likely to be lower than 417 the AUC of either LUM or DBL alone in subjects with recurrent parasitemia at days 28 and 418 42. This supports the suggestion that DBL may influence AL treatment outcome (33). 419 
